The previously reported lower concordance levels of KRAS between the primary tumor and metastases are likely due to bias arising from false-negative results in underpowered studies and the correct evaluation of the amount of tumor tissue in the sample, or the sensitivity of the testing method used [6]. This evidence concerns the gene KRAS and neoplasm.